Eric Topol October 20, 2025
Reviewing the new data and the “liquid biopsy” field
At the European Society of Medical Oncology (ESMO) meeting last week, the largest study of multi-cancer early detection blood test (MCED) was presented for the first time. I’ve reviewed this topic in SUPER AGERS but this trial of nearly 36,000 participants represents a significant update. In this issue of Ground Truths, I’ll get into the data, implications, and where the field is headed.
The PATHFINDER 2 Trial and Results
This new study assessed the GRAIL blood test called Galleri that assesses DNA-methylation markers (side chains of DNA) in the plasma from patterns in cell-free cancer fragments, a so-called “cancer signal.” The new trial was preceded by PATHFINDER, a study of 6,602...
Today's Sponsors
Today's Sponsor